BackTonix Pharmaceuticals Holding Overview

Tonix Pharmaceuticals Holding Total Liabilities

Latest total liabilities for TNXP: $32M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$31.81M
64.31% YoYΔ $12.45M vs prior year quarter

Peer trimmed avg / median

Loading

Tonix Pharmaceuticals Holding Total Liabilities History

Loading

Tonix Pharmaceuticals Holding vs. peers: Total Liabilities Comparison

Loading

Tonix Pharmaceuticals Holding Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Tonix Pharmaceuticals Holding (TNXP) FAQ

Tonix Pharmaceuticals Holding's total liabilities stands at $32M as of June 2026. That compares with $19M in the prior-year period — up 64.3% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Tonix Pharmaceuticals Holding reported $32M in total liabilities versus $19M a year earlier — a 64.3% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $19M in the prior-year period — up 64.3% year over year. Sustained growth in total liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Tonix Pharmaceuticals Holding's total liabilities evolved across reporting periods, while the comparison chart places TNXP next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total liabilities is commonly used to spot outliers. Tonix Pharmaceuticals Holding's reading of $32M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.